Premium
Bacteriocin nanoconjugates: boon to medical and food industry
Author(s) -
Sulthana R.,
Archer A.C.
Publication year - 2021
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/jam.14982
Subject(s) - bacteriocin , antimicrobial , antibiotics , antibiotic resistance , antimicrobial peptides , proteolytic enzymes , microbiology and biotechnology , food industry , anti infective agents , drug resistance , bacteria , biology , chemistry , enzyme , biochemistry , food science , genetics
Summary Resistance to antibiotics is an ongoing problem in the biomedical industry. Developing active, alternative drug therapies would reduce our reliance on antibiotics that induce resistance in micro‐organisms. To date, bacteriocins and antimicrobial peptides have shown a positive outcome as antibiotic substitutes and synergists apart from phage therapy, antibodies and probiotics. Bacteriocins are proteinaceous antimicrobial peptides synthesized by lactic acid bacteria extensively used as bio‐preservatives and alternative to traditional antibiotics to overcome the problem of drug‐resistant pathogens. Nonetheless, the use of bacteriocins has several limitations such as limited antimicrobial spectrum, requiring high dose, sensitivity to proteolytic enzymes, etc. Nanoparticles are one of the promising area of research explored to improve antimicrobial spectrum of bacteriocins. This review therefore highlights the recent developments and research pertaining to use of nanoparticles and bacteriocin conjugates to tackle the resistance crisis as well as its applications in food industry.